RU2011136280A - HE-Ad5 АДЕНОВИРУСНЫЕ ВЕКТОРЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ, СВЯЗАННЫЕ С НИМИ - Google Patents
HE-Ad5 АДЕНОВИРУСНЫЕ ВЕКТОРЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ, СВЯЗАННЫЕ С НИМИ Download PDFInfo
- Publication number
- RU2011136280A RU2011136280A RU2011136280/10A RU2011136280A RU2011136280A RU 2011136280 A RU2011136280 A RU 2011136280A RU 2011136280/10 A RU2011136280/10 A RU 2011136280/10A RU 2011136280 A RU2011136280 A RU 2011136280A RU 2011136280 A RU2011136280 A RU 2011136280A
- Authority
- RU
- Russia
- Prior art keywords
- cancer
- adenoviral vector
- human
- vector according
- oncolytic
- Prior art date
Links
- 239000013598 vector Substances 0.000 title claims abstract 38
- 238000000034 method Methods 0.000 title claims 13
- 241000701161 unidentified adenovirus Species 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 claims abstract 26
- 230000000174 oncolytic effect Effects 0.000 claims abstract 26
- 108700019146 Transgenes Proteins 0.000 claims abstract 12
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims abstract 4
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims abstract 4
- 230000010076 replication Effects 0.000 claims abstract 3
- 108010029697 CD40 Ligand Proteins 0.000 claims abstract 2
- 102100032937 CD40 ligand Human genes 0.000 claims abstract 2
- 102000006992 Interferon-alpha Human genes 0.000 claims abstract 2
- 108010047761 Interferon-alpha Proteins 0.000 claims abstract 2
- 102000003996 Interferon-beta Human genes 0.000 claims abstract 2
- 108090000467 Interferon-beta Proteins 0.000 claims abstract 2
- 102000008070 Interferon-gamma Human genes 0.000 claims abstract 2
- 108010074328 Interferon-gamma Proteins 0.000 claims abstract 2
- 229960003130 interferon gamma Drugs 0.000 claims abstract 2
- 229960001388 interferon-beta Drugs 0.000 claims abstract 2
- 229960000575 trastuzumab Drugs 0.000 claims abstract 2
- 201000011510 cancer Diseases 0.000 claims 19
- 206010009944 Colon cancer Diseases 0.000 claims 10
- 208000003174 Brain Neoplasms Diseases 0.000 claims 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 6
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 6
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 6
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 6
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 6
- 201000002528 pancreatic cancer Diseases 0.000 claims 6
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 6
- 208000014018 liver neoplasm Diseases 0.000 claims 5
- 206010005949 Bone cancer Diseases 0.000 claims 4
- 208000018084 Bone neoplasm Diseases 0.000 claims 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 4
- 208000005890 Neuroma Diseases 0.000 claims 4
- 208000000821 Parathyroid Neoplasms Diseases 0.000 claims 4
- 206010038389 Renal cancer Diseases 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 208000029742 colonic neoplasm Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims 4
- 201000010982 kidney cancer Diseases 0.000 claims 4
- 201000005202 lung cancer Diseases 0.000 claims 4
- 208000020816 lung neoplasm Diseases 0.000 claims 4
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 claims 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 3
- 101000716693 Homo sapiens Sodium/iodide cotransporter Proteins 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 229910052740 iodine Inorganic materials 0.000 claims 3
- 239000011630 iodine Substances 0.000 claims 3
- 201000007270 liver cancer Diseases 0.000 claims 3
- 230000002285 radioactive effect Effects 0.000 claims 3
- 210000001519 tissue Anatomy 0.000 claims 3
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims 2
- 206010061424 Anal cancer Diseases 0.000 claims 2
- 206010004593 Bile duct cancer Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010007270 Carcinoid syndrome Diseases 0.000 claims 2
- 208000009458 Carcinoma in Situ Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 208000005243 Chondrosarcoma Diseases 0.000 claims 2
- 208000006332 Choriocarcinoma Diseases 0.000 claims 2
- 206010014733 Endometrial cancer Diseases 0.000 claims 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 2
- 201000008808 Fibrosarcoma Diseases 0.000 claims 2
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 2
- 206010018691 Granuloma Diseases 0.000 claims 2
- 208000017604 Hodgkin disease Diseases 0.000 claims 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 2
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 2
- 206010023825 Laryngeal cancer Diseases 0.000 claims 2
- 206010062038 Lip neoplasm Diseases 0.000 claims 2
- 206010027406 Mesothelioma Diseases 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 2
- 206010029260 Neuroblastoma Diseases 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 201000010133 Oligodendroglioma Diseases 0.000 claims 2
- 208000010191 Osteitis Deformans Diseases 0.000 claims 2
- 208000000035 Osteochondroma Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 208000027868 Paget disease Diseases 0.000 claims 2
- 208000002471 Penile Neoplasms Diseases 0.000 claims 2
- 206010034299 Penile cancer Diseases 0.000 claims 2
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 claims 2
- 206010034811 Pharyngeal cancer Diseases 0.000 claims 2
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 206010036832 Prolactinoma Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 2
- 201000000582 Retinoblastoma Diseases 0.000 claims 2
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims 2
- 206010061934 Salivary gland cancer Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 2
- 206010041329 Somatostatinoma Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000000389 T-cell leukemia Diseases 0.000 claims 2
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 claims 2
- 206010042971 T-cell lymphoma Diseases 0.000 claims 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 2
- 206010057644 Testis cancer Diseases 0.000 claims 2
- 208000000728 Thymus Neoplasms Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 206010062129 Tongue neoplasm Diseases 0.000 claims 2
- 206010044002 Tonsil cancer Diseases 0.000 claims 2
- 208000006842 Tonsillar Neoplasms Diseases 0.000 claims 2
- 206010046431 Urethral cancer Diseases 0.000 claims 2
- 206010046458 Urethral neoplasms Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 2
- 208000008383 Wilms tumor Diseases 0.000 claims 2
- 230000003187 abdominal effect Effects 0.000 claims 2
- 201000005188 adrenal gland cancer Diseases 0.000 claims 2
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims 2
- 201000007696 anal canal cancer Diseases 0.000 claims 2
- 208000026900 bile duct neoplasm Diseases 0.000 claims 2
- 229940022399 cancer vaccine Drugs 0.000 claims 2
- 238000009566 cancer vaccine Methods 0.000 claims 2
- 208000002458 carcinoid tumor Diseases 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 2
- 210000000860 cochlear nerve Anatomy 0.000 claims 2
- 201000010918 connective tissue cancer Diseases 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- 208000024519 eye neoplasm Diseases 0.000 claims 2
- 201000010175 gallbladder cancer Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 230000002496 gastric effect Effects 0.000 claims 2
- 208000015419 gastrin-producing neuroendocrine tumor Diseases 0.000 claims 2
- 201000000052 gastrinoma Diseases 0.000 claims 2
- 201000005459 gum cancer Diseases 0.000 claims 2
- 201000010235 heart cancer Diseases 0.000 claims 2
- 208000024348 heart neoplasm Diseases 0.000 claims 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 206010022498 insulinoma Diseases 0.000 claims 2
- 238000001361 intraarterial administration Methods 0.000 claims 2
- 238000007918 intramuscular administration Methods 0.000 claims 2
- 230000002601 intratumoral effect Effects 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 206010023841 laryngeal neoplasm Diseases 0.000 claims 2
- 201000006721 lip cancer Diseases 0.000 claims 2
- 208000026037 malignant tumor of neck Diseases 0.000 claims 2
- 208000027202 mammary Paget disease Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 206010027191 meningioma Diseases 0.000 claims 2
- 201000008026 nephroblastoma Diseases 0.000 claims 2
- 210000005036 nerve Anatomy 0.000 claims 2
- 230000003472 neutralizing effect Effects 0.000 claims 2
- 201000008106 ocular cancer Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 208000028591 pheochromocytoma Diseases 0.000 claims 2
- 201000002511 pituitary cancer Diseases 0.000 claims 2
- 201000003437 pleural cancer Diseases 0.000 claims 2
- 208000030153 prolactin-producing pituitary gland adenoma Diseases 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- 206010038038 rectal cancer Diseases 0.000 claims 2
- 201000001275 rectum cancer Diseases 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 208000037959 spinal tumor Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 201000003120 testicular cancer Diseases 0.000 claims 2
- 201000009377 thymus cancer Diseases 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 201000006134 tongue cancer Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 206010046766 uterine cancer Diseases 0.000 claims 2
- 206010046885 vaginal cancer Diseases 0.000 claims 2
- 208000013139 vaginal neoplasm Diseases 0.000 claims 2
- 208000006542 von Hippel-Lindau disease Diseases 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 claims 1
- 241000598171 Human adenovirus sp. Species 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 241000282320 Panthera leo Species 0.000 claims 1
- 108010017842 Telomerase Proteins 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 206010047741 Vulval cancer Diseases 0.000 claims 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 201000002313 intestinal cancer Diseases 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000003254 palate Anatomy 0.000 claims 1
- 208000021255 pancreatic insulinoma Diseases 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 201000005102 vulva cancer Diseases 0.000 claims 1
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 abstract 3
- 102000003673 Symporters Human genes 0.000 abstract 1
- 108090000088 Symporters Proteins 0.000 abstract 1
- 230000017074 necrotic cell death Effects 0.000 abstract 1
- 235000009518 sodium iodide Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10345—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10371—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20090030A FI20090030A0 (fi) | 2009-02-02 | 2009-02-02 | Onkolyyttiset virukset |
| FI20090030 | 2009-02-02 | ||
| FI20095751 | 2009-07-02 | ||
| FI20095751A FI121574B (fi) | 2009-02-02 | 2009-07-02 | Ei-Ad5 adenovirusvektoreita ja niihin liittyviä menetelmiä ja käyttöjä |
| PCT/IB2010/050452 WO2010086838A2 (en) | 2009-02-02 | 2010-02-02 | Non-ad5 adenoviral vectors and methods and uses related thereto |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2011136280A true RU2011136280A (ru) | 2013-03-10 |
Family
ID=40404558
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011136280/10A RU2011136280A (ru) | 2009-02-02 | 2010-02-02 | HE-Ad5 АДЕНОВИРУСНЫЕ ВЕКТОРЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ, СВЯЗАННЫЕ С НИМИ |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20120063995A1 (enExample) |
| EP (1) | EP2391722B1 (enExample) |
| JP (1) | JP2012516682A (enExample) |
| KR (1) | KR20110110371A (enExample) |
| CN (1) | CN102325887A (enExample) |
| AU (1) | AU2010209334A1 (enExample) |
| BR (1) | BRPI1008159A2 (enExample) |
| CA (1) | CA2750770A1 (enExample) |
| FI (2) | FI20090030A0 (enExample) |
| RU (1) | RU2011136280A (enExample) |
| SG (1) | SG173502A1 (enExample) |
| WO (1) | WO2010086838A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2619224A1 (en) * | 2010-09-24 | 2013-07-31 | Oncos Therapeutics Oy | Oncolytic adenoviral vectors and methods and uses related thereto |
| US12421502B2 (en) | 2013-04-18 | 2025-09-23 | Tilt Biotherapeutics Oy | Enhanced adoptive cell therapy |
| WO2014170389A1 (en) * | 2013-04-18 | 2014-10-23 | Tilt Biotherapeutics Oy | Enhanced adoptive cell therapy |
| CN104946602A (zh) * | 2015-06-11 | 2015-09-30 | 华中科技大学同济医学院附属同济医院 | 具有肿瘤组织靶向性和抑癌基因修复性的重组溶瘤腺病毒Ad5-P16及其应用 |
| HUE053236T2 (hu) * | 2016-09-12 | 2021-06-28 | Targovax Oy | Adenovírus és ellenõrzõpont-gátlók kombinálása rák kezelésére |
| CN108261426B (zh) * | 2017-01-04 | 2019-04-05 | 杭州康万达医药科技有限公司 | 药物组合物及其在治疗肿瘤和/或癌症的药物中的应用 |
| US20190352669A1 (en) * | 2017-01-30 | 2019-11-21 | Epicentrx, Inc. | Tumor selective tata-box and caat-box mutants |
| EP3773649A4 (en) | 2018-03-28 | 2022-02-23 | EpicentRx, Inc. | PERSONALIZED CANCER VACCINE |
| CN112912389B (zh) * | 2018-06-19 | 2024-04-19 | H·李·莫菲特癌症中心和研究所公司 | 使用i型干扰素和cd40配体的溶瘤病毒或抗原呈递细胞介导的癌症治疗 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2527369A1 (en) * | 2003-07-18 | 2005-02-03 | Onyx Pharmaceuticals, Inc. | Subgroup b adenoviral vectors for treating disease |
| AU2003265873A1 (en) * | 2003-08-28 | 2005-04-14 | Cell Genesys, Inc. | Oncolytic adenoviral vectors encoding gm-csf |
| US7473418B2 (en) * | 2004-03-25 | 2009-01-06 | Cell Genesys, Inc. | Pan cancer oncolytic vectors and methods of use thereof |
-
2009
- 2009-02-02 FI FI20090030A patent/FI20090030A0/fi not_active Application Discontinuation
- 2009-07-02 FI FI20095751A patent/FI121574B/fi not_active IP Right Cessation
-
2010
- 2010-02-02 JP JP2011547047A patent/JP2012516682A/ja active Pending
- 2010-02-02 AU AU2010209334A patent/AU2010209334A1/en not_active Abandoned
- 2010-02-02 US US13/147,288 patent/US20120063995A1/en not_active Abandoned
- 2010-02-02 CA CA2750770A patent/CA2750770A1/en not_active Abandoned
- 2010-02-02 EP EP10704194.9A patent/EP2391722B1/en not_active Not-in-force
- 2010-02-02 RU RU2011136280/10A patent/RU2011136280A/ru not_active Application Discontinuation
- 2010-02-02 KR KR1020117020181A patent/KR20110110371A/ko not_active Withdrawn
- 2010-02-02 BR BRPI1008159A patent/BRPI1008159A2/pt not_active IP Right Cessation
- 2010-02-02 CN CN2010800087768A patent/CN102325887A/zh active Pending
- 2010-02-02 WO PCT/IB2010/050452 patent/WO2010086838A2/en not_active Ceased
- 2010-02-02 SG SG2011055563A patent/SG173502A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2750770A1 (en) | 2010-08-05 |
| FI20095751A0 (fi) | 2009-07-02 |
| US20120063995A1 (en) | 2012-03-15 |
| SG173502A1 (en) | 2011-09-29 |
| EP2391722B1 (en) | 2014-06-11 |
| WO2010086838A2 (en) | 2010-08-05 |
| FI20090030A0 (fi) | 2009-02-02 |
| BRPI1008159A2 (pt) | 2016-03-29 |
| CN102325887A (zh) | 2012-01-18 |
| JP2012516682A (ja) | 2012-07-26 |
| FI121574B (fi) | 2011-01-14 |
| FI20095751L (fi) | 2010-08-03 |
| WO2010086838A3 (en) | 2010-11-25 |
| KR20110110371A (ko) | 2011-10-06 |
| EP2391722A2 (en) | 2011-12-07 |
| AU2010209334A1 (en) | 2011-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2011136280A (ru) | HE-Ad5 АДЕНОВИРУСНЫЕ ВЕКТОРЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ, СВЯЗАННЫЕ С НИМИ | |
| RU2011130511A (ru) | Аденовирусные векторы и способы их применения, связанные с ними | |
| RU2013118724A (ru) | Онколитические аденовирусные векторы и связанные с ними способы и применения | |
| RU2013118723A (ru) | Онколитические аденовирусные векторы, кодирующие моноклональные антитела против ctla-4 | |
| RU2017134275A (ru) | Онколитические аденовирусы, кодирующие биспецифические антитела, а также способы и применения, связанные с ними | |
| US9410129B2 (en) | Recombinant serotype 5 (Ad5) adenoviral vectors | |
| JP2012516682A5 (enExample) | ||
| JP2012513209A5 (enExample) | ||
| US12291726B2 (en) | A549 host cells comprising a recombinant oncolytic adenovirus with modified E1A cancer-specific promoter | |
| FI3768830T3 (fi) | Syöpäterapia | |
| US20200078415A1 (en) | Multiple transgene recombinant adenovirus | |
| MX2025001237A (es) | Celulas modificadas geneticamente con expresion genica reducida para mitigar el reconocimiento de celulas inmunitarias | |
| CN108342366B (zh) | 靶向癌症的重组溶瘤基因-腺病毒及其构建方法和应用 | |
| CN102229962B (zh) | 纤维蛋白修饰表达两个外源基因的溶瘤腺病毒载体及构建方法和应用 | |
| CN111534530A (zh) | 一种光感细胞焦亡质粒的设计方法 | |
| CN101671666B (zh) | 用于恶性肿瘤基因治疗的增殖和肿瘤细胞特异性基因操纵系统 | |
| Ma et al. | E2F promoter-regulated oncolytic adenovirus with p16 gene induces cell apoptosis and exerts antitumor effect on gastric cancer | |
| CN117003897B (zh) | 靶向Claudin18.2的CAR-T细胞及其用途 | |
| RU2012100903A (ru) | Терапевтические пептиды, полипептиды и последовательности нуклеиновых кислот | |
| CN117417962B (zh) | 一种多靶点溶瘤腺病毒的构建方法及应用 | |
| JP2013215104A (ja) | アデノウイルスベクターをがん細胞に対して選択的に導入可能なポリペプチドおよび当該ポリペプチドを備えるアデノウイルスベクター | |
| WO2010114143A1 (ja) | 特異的プロモーターの活性を上昇させるシステム及び該システムを保持したベクター | |
| CN101880688B (zh) | 一种使复制缺陷型腺病毒选择性复制的方法和用途 | |
| Jiang et al. | A gutless adenoviral vector expressing full-length anti-Her2 antibody. | |
| CN101744848A (zh) | Fhl3在制备用于治疗肿瘤的药物中的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA94 | Acknowledgement of application withdrawn (non-payment of fees) |
Effective date: 20150623 |